Data Safety Monitoring Board Gives Positive Review For BioMS Medical's Pivotal MS Trial

EDMONTON, Oct. 27 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that following the second meeting of its independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. This second recommendation by the DSMB members was based on their recent review of the safety data from patients who have been dosed in the pivotal phase II/III clinical study.

Back to news